Diagnosis or prognosis of lung cancer and colorectal cancer based on expression level of glutaredoxin 3
AssigneePaichi University Industry-Academic Cooperation Foundation
InventorIl Han Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a biomarker for diagnosing lung cancer and colorectal cancer containing glutaredoxin 3 as an active ingredient, and a kit for diagnosing lung cancer and colorectal cancer using the same biomarker. Glutaredoxin 3 of the present invention is over-expressed in lung cancer tissue and colorectal cancer tissue, which enables early prediction of diagnosis or prognosis of lung cancer and colorectal cancer. Thus, glutaredoxin 3 can be helpfully used as a biomarker for diagnosing lung cancer and colorectal cancer.
Claims6
A method of diagnosis or prognosis of lung cancer in a subject, the method comprising:
- providing a tissue of the subject;
- processing the tissue to isolate mRNAs contained in the tissue;
- generating cDNAs complementary to the isolated mRNAs;
- mixing the cDNAs with a forward rimer consisting of SEQ ID NO:
- 5 and a reverse primer consisting of SEQ ID NO:
- 6, which to provide a mixture;
- performing a qRT-PCR using the mixture and a PCR composition to amplify one or more cDNA sequences recognized by the forward and reverse primers;
- determining an expression level of glutaredoxin 3 in the tissue based on results of the qRT-PCR;
- and
- diagnosing or prognosing lung cancer when the expression level is higher than a reference value.
A method of diagnosis or prognosis of colorectal cancer in a subject, the method comprising:
- providing a tissue of the subject;
- processing the tissue to isolate mRNAs contained in the tissue;
- generating cDNAs complementary to the isolated mRNAs;
- mixing the cDNAs with a forward primer consisting of SEQ ID NO:
- 5 and a reverse primer consisting of SEQ ID NO:
- 6, which to provide a mixture;
- performing a qRT-PCR using the mixture and a PCR composition to amplify one or more cDNA sequences recognized by the forward and reverse primers;
- determining an expression level of glutaredoxin 3 in the tissue based on results of the qRT-PCR;
- and
- diagnosing or prognosing colorectal cancer when the expression level is higher than a reference value.
Dependencies are inferred from the claim text.